What You Should Know:
–DCAI today announced that Novo Nordisk has become a customer of the Gefion AI supercomputer.
– Through this agreement, Novo Nordisk will gain access to Gefion’s unparalleled computational capabilities to process vast datasets, with a goal of transforming drug discovery and development as well as driving healthcare innovation.
AI-Powered Supercomputing Alliance to Advance Drug Discovery at Scale
In a landmark multiyear agreement, Novo Nordisk and Gefion have partnered to accelerate pharmaceutical innovation by integrating next-generation AI and high-performance computing. This collaboration combines Novo Nordisk’s deep expertise in drug discovery with Gefion’s advanced NVIDIA DGX SuperPod infrastructure—currently ranked 21st on the Top500 list of the world’s most powerful supercomputers.
The partnership is expected to:
· Accelerate the development of novel therapies by significantly reducing research timelines
· Support compute-intensive R&D initiatives across Novo Nordisk’s AI-driven drug discovery pipeline
· Enable large-scale simulations, model development, and advanced analytics that would otherwise be computationally prohibitive
Gefion’s robust technology stack is built to meet the demands of both academic and industry researchers. Its scalable architecture empowers teams to conduct experiments at unprecedented speed and complexity, positioning it as a cornerstone platform for data-intensive pharmaceutical research.
Novo Nordisk has identified AI as a strategic priority across its value chain. The company has also formed a separate collaboration with NVIDIA to build customized AI models that support early-stage research and discovery. Gefion will serve as a critical enabler of these initiatives by providing the computational power necessary to unlock next-generation scientific insights.
Commenting on the collaboration, Nadia Carlsten, CEO of DCAI, noted: “Working alongside Novo Nordisk, we can use Gefion to redefine what is possible in drug research. With Gefion’s compute power, we aim to address the most complex R&D challenges and accelerate time-to-discovery, ultimately unlocking new possibilities in pharmaceutical innovation.”
